Discrimination between active and latent tuberculosis based on ratio of antigen-specific to mitogen-induced IP-10 production by 媛뺤쁺�븷 et al.
Discrimination between Active and Latent Tuberculosis Based on
Ratio of Antigen-Specific to Mitogen-Induced IP-10 Production
Yun Hee Jeong,a Yun-Gyoung Hur,b Hyejon Lee,b Sunghyun Kim,c Jang-Eun Cho,d Jun Chang,e Sung Jae Shin,b Hyeyoung Lee,c
Young Ae Kang,f Sang-Nae Cho,b Sang-Jun Haa
Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Koreaa; Department of Microbiology, Yonsei University
College of Medicine, Seoul, Republic of Koreab; Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, Wonju, Gangwon, Republic
of Koreac; Department of Biomedical Laboratory Science, Daegu Health College, Daegu, Republic of Koread; Division of Life and Pharmaceutical Sciences, College of
Pharmacy, Ewha Woman’s University, Seoul, Republic of Koreae; Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul,
Republic of Koreaf
Mycobacterium tuberculosis is the major causative agent of tuberculosis (TB). The gamma interferon (IFN-) release assay
(IGRA) has been widely used to diagnose TB by testing cell-mediated immune responses but has no capacity for distinguishing
between active TB and latent TB infection (LTBI). This study aims to identify a parameter that will help to discriminate active TB
and LTBI. Whole-blood samples from 33 active TB patients, 20 individuals with LTBI, and 26 non-TB controls were applied to
the commercial IFN- release assay, QuantiFERON-TB Gold In-Tube, and plasma samples were analyzed for interleukin-2 (IL-
2), IL-6, IL-8, IL-10, IL-13, tumor necrosis factor-alpha (TNF-), IFN-, monokine induced by IFN- (MIG), interferon gamma
inducible protein 10 (IP-10), interferon-inducible T cell alpha chemoattractant (I-TAC), andmonocyte chemoattractant protein
1 (MCP-1) by using a commercial cytometric bead array. TheMycobacterium tuberculosis antigen-specific production of most of
the assayed cytokines and chemokines was higher in the active TB than in the LTBI group. The mitogen-induced responses were
lower in the active TB than in the LTBI group.When the ratio of TB-specific to mitogen-induced responses was calculated, IL-2,
IL-6, IL-10, IL-13, TNF-, IFN-, MIG, and IP-10 were more useful in discriminating active TB from LTBI. In particular, most
patients showed higher IP-10 production toMycobacterium tuberculosis antigens than to mitogen at the individual level, and the
ratio for IP-10 was the strongest indicator of active infection versus LTBI with 93.9% sensitivity and 90% specificity. In conclu-
sion, the ratio of the TB-specific to the mitogen-induced IP-10 responses showed the most promising accuracy for discriminat-
ing active TB versus LTBI and should be further studied to determine whether it can serve as a biomarker that might help clini-
cians administer appropriate treatments.
Mycobacterium tuberculosis, the major causative agent for tu-berculosis (TB), is among themost successful human patho-
gens, infecting approximately 8.6 million people and leading to
1.3 million deaths each year (1). It is estimated that 2 billion peo-
ple live with latent TB infection (LTBI) and are therefore a poten-
tial source of active TB (2, 3). Identifying LTBI is necessary in
order to reduce the risk of development of the disease, while diag-
nosis of active TB can enable rapid treatment and disease control.
To this end, diagnostic biomarkers that can accurately indicate
disease status are needed (4, 5).
There is presently no diagnostic gold standard for LTBI. Until
recently, the tuberculin skin test (TST) involving the intracutane-
ous injection of purified protein derivative (PPD) into the fore-
armwas the only availablemethod for diagnosing LTBI.However,
PPD cross-reacts with nontuberculous mycobacteria as well as
withMycobacterium bovis bacille Calmette-Guérin (BCG) vaccine
and has poor sensitivity in immunocompromised patients (6).
The interferon gamma (IFN-) release assay (IGRA) has been
widely used in clinical practice and public health policy for TB
diagnosis (7). Commercial IGRAs such as the QuantiFERON-TB
Gold In-Tube test (QFT-GIT) measure responses to M. tubercu-
losis-specific antigens, including early secretory antigenic target-6
(ESAT-6), culture filtrate protein 10 (CFP-10), and TB7.7 anti-
gens, and discriminate between aM. tuberculosis infection and an
immunity-induced response to BCG vaccination (8, 9). The IGRA
therefore seems to be useful for the diagnosis of TB in individuals
who have been recently vaccinated with BCG and those who are
immunocompromised. However, IGRAs have only shown medi-
ocre results in the latter group and are also unable to discriminate
between active TB and LTBI (10).
In addition to IFN-, many cytokines and chemokines have been
investigated as potential biomarkers for M. tuberculosis infection
and disease status (11–18). The levels of several cytokines, includ-
ing interleukin-6 (IL-6), IL-10, IL-15, chemokine (C-X-C) motif
ligand (CXCL)/interferon gamma-inducible protein 10 (IP-10),
and monocyte chemoattractant protein 2 (MCP-2), were signifi-
cantly higher in TB patients than in healthy controls (7, 11, 18–
21); although these finding suggest important roles for these fac-
tors in disease pathogenesis, they are not sufficient for diagnosing
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active as opposed to latent infections. Several studies have also
suggested that biomarker combinations such as IFN-tumor
necrosis factor alpha (TNF-), IFN-IL-2, IFN-IL-4, and
IL-15MCP-1 might be more sensitive than single markers (18,
22–24). However, a better biomarker to improve the sensitivity
and specificity in discriminating between active TB and LTBI is
still needed.
The current studywas designed to develop a newbiomarker for
the diagnosis of different stages of M. tuberculosis infection. Par-
ticipants were recruited following approval of the protocol by the
ethics review committee. Interestingly, during our study, we
found that the method for calculating the ratio of IP-10 levels in
response to TB antigens and mitogen might be more sensitive in
discriminating patients with active TB from individuals with LTBI
or healthy controls without TB than that for measuring the con-
centrations of TB antigen-induced IP-10 or any other cytokines
and chemokines that we have tested in this study.
MATERIALS AND METHODS
Study population. Participants were recruited from November 2010 to
October 2012 following approval of the protocol by the Severance Hospi-
tal Ethics Review Committee (institutional review board [IRB] no.
4-2010-0213). All study subjects gave informed consent for the use of the
samples obtained. The diagnosis of active pulmonary TB was based on all
clinical, radiological, microbiological, and pathological results. Active TB
was confirmed by culture ofM. tuberculosis from respiratory specimens or
by the presence of caseating granulomas in lung tissue. Patients with lym-
phocyte-predominant exudative effusions and adenosine deaminase lev-
els of 40 IU/liter or those with a high likelihood of active TB based on
clinical and radiological results were included if their conditions im-
proved after antituberculosis treatment. In detail, among a total of 33
active TB patients, 25 patients were diagnosed as having active TB based
on positive cultures ofM. tuberculosis and 2 patients were diagnosed based
on pathological results, which showed chronic granulomatous inflamma-
tion and positive PCRs. The remaining 6 patients were diagnosed based
on the clinical and the radiological information. Since their chest com-
puted tomography scans showed typical centrilobular nodules on their
upper lungs, which resolved after a full-course of anti-TB treatment, they
were finally classified as having active TB. The LTBI group consisted of
household members with positive TST (10mm), who had been in close
contact and lived with a patient with microbiologically confirmed active
pulmonary TB for longer than 1 month (25). None of the household
contacts showed the clinical symptoms or chest radiographic findings
indicative of TB. The non-TB control group consisted of healthy adults
with a negative TST, who were free of TB symptoms and did not have any
contact with active pulmonary TB patients. All control subjects had nor-
mal chest X-ray results.
TST. Skin tests were performed using RT-23 tuberculin (Statens Se-
rum Institute, Copenhagen, Denmark). The induration was measured 48
to 72 h later, and the cutoff for a positive result in immunocompetent
subjects was 10 mm, according to the Korean TB guideline (25).
IFN-determinationbyQFT-GIT assay.The IFN- release assaywas
performed using the QFT-GIT assay kit. Briefly, 1 ml whole blood was
drawn into the three QFT-GIT tubes precoated with saline (control), M.
tuberculosis-specific antigens (ESAT-6, CFP-10, and TB7.7), or mitogen
and incubated for 20 h at 37°C. After centrifugation, the supernatant was
collected and stored frozen at 20°C until the IFN- concentration was
determined by an enzyme-linked immunosorbent assay (ELISA) using a
QFT Gold kit. The results were calculated using the manufacturer’s QFT-
GIT software. With the QFT Gold kits, we used 7 kinds of tubes with
different lot numbers (80181, 80221, 80231, 80261, 80321, 80401, and
80451).
Multiplex analysis of cytokine production. Levels of IL-2, IL-6, IL-8,
IL-10, IL-13, TNF-, IFN-, monokine induced by IFN- (MIG), IP-10,
I-TAG, and MCP-1 were measured in the supernatants described above
with commercial cytometric bead array human cytokine and chemokine
flex sets (BD Biosciences, San Jose, CA, USA) according to the manufac-
turer’s recommendations.
Data analysis.Datawere analyzed usingGraphPad Prism version 5.02
(GraphPad Software, San Diego, CA, USA). Variables that were not nor-
mally distributed were compared across and within groups using the
nonparametricMann-Whitney test. Antigen-dependent andmitogen-in-
duced biomarker production values were measured by subtracting the
concentration measured in the control tube from those measured in the
antigen and mitogen tubes, respectively. The diagnostic performances of
the antigen-dependent and mitogen-induced biomarker values were
comparedwith a receiver operating characteristic (ROC) curve analysis to
determine the area under the curve (AUC) and the optimal cutoff levels.
RESULTS
Characteristics of the study population. The study included 33
patients with active pulmonary TB, 20 subjects with LTBI, and 26
non-TB controls (Table 1). The LTBI group was slightly older than
the other groups:median ages were 44 years (range, 22–60 years) for
the LTBI group, 30 years (range, 20–63 years) for the active TB
group, and 25 years (range, 22–54 years) for the non-TB control
group. Themale to female ratioswere 4/16, 19/12, and 12/14, respec-
tively, and BCG scars were seen in 18 (90%), 21 (63.6%), and 14
(53.8%) of the subjects, respectively. For the QFT-GIT assay, results
for all of the non-TB controls were negative; positive results were
observed in 11 (55%) subjects with LTBI and all 33 (100%) patients
with active TB.We defined the LTBI group as TST-positive individ-
uals who had been in close contact and lived with patients with mi-
crobiologically confirmed active pulmonary TB for longer than 1
month, according to the Korean TB guidelines (25).
Comparisonof cytokine and chemokine levels in response to
TB antigens or mitogen. To identify new biomarkers for detect-
ing active TB and discriminating LTBI, the levels of 11 cytokines
and chemokines were evaluated (Fig. 1). The baseline levels of all
cytokines, as observed in unstimulatedwhole-blood samples from
each group, were subtracted from the corresponding levels in TB
antigen- and mitogen-stimulated samples.
The median levels of IL-2, IL-6, IL-13, MIG, IP-10, I-TAG,
MCP-1, and IL-8were higher in active TBpatients than in non-TB
TABLE 1 Characteristics of the study subjects for the multicytokine
assay
Characteristica
Result forb:
Controls
(n 26)
LTBI subjects
(n 20)
Active TB patients
(n 33)
Age (median [range]) (yrs) 25 (22–54) 44 (22–60) 30 (20–63)
Sex (male/female) 12/14 4/16 19/12
Presence of a BCG scar
(n [%])
14 (53.8) 18 (90) 21 (63.6)
Positive TST (n [%]) 20 (100) 3 (75) (29 NDc)
Pulmonary TB diagnosis
Positive AFB culture
(n [%])
25 (75.8)
Positive QFT-GIT result
(n [%])
0 (0) 11 (55) 33 (100)
a AFB, acid-fast bacilli; BCG, bacille Calmette-Guérin; QFT-GIT, QuantiFERON-TB
Gold In-Tube test; TST, tuberculin skin test.
b LTBI, latent tuberculosis infection; TB, tuberculosis.
c ND, not determined.
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controls, in accordance with IFN- responses measured by the
QFT-GIT assay. In addition, IL-2, IL-6, IL-10, IL-13, TNF-,
MIG, IP-10, and I-TAG levels were higher in active TB patients
than in LTBI subjects, which was also consistent with the IFN-
response. The levels of these factors differed significantly between
samples from non-TB controls and active TB patients and be-
tween samples from active TB patients and LTBI subjects, imply-
ing that they are potentially useful biomarkers.
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FIG 1 Cytokine levels in active TB and LTBI. Whole blood was stimulated withM. tuberculosis-specific antigens (ESAT-6, CFP-10, and TB7.7) or with mitogen
for 24 h, and the levels of TB-specific and mitogen-induced cytokines and chemokines were measured in active TB patients, LTBI subjects, and non-TB healthy
control subjects. *P 0.05; **P 0.01; ***P 0.001; ns, not significant.
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Ratio of TB-specific to mitogen-induced responses. While
analyzing the responses after stimulation of whole-blood samples
with TB antigens or mitogen, we found that the levels of IL-2,
IL-10, IL-13, IL-8, and IFN- in response to mitogen were rela-
tively lower in active TB patients than in LTBI individuals (Fig. 1).
Even though this phenomenon had been previously observed in
some studies (13, 26), it has not been seriously considered. Based
on our finding, the ratio of TB antigen-specific to mitogen-in-
duced nonspecific responses was therefore calculated in individ-
ual samples (Fig. 2A). Interestingly, the ratios for IL-2, IL-6, IL-13,
TNF-, MIG, IP-10, I-TAG, IL-8, and IFN- were markedly
higher in active TB patients than in non-TB controls. In addition,
the ratios for IL-2, IL-6, IL-10, IL-13, TNF-, MIG, IP-10, and
IFN- were higher in active TB patients than in LTBI individuals.
The diagnostic performances of the biomarkers were evaluated
using ROC curves. The AUC is widely recognized as a measure of
the discriminatory ability of a diagnostic test; in general, ROC
curves with an AUC of 0.8 are considered to have good diagnostic
ability. The biomarkers with potential (AUC values of 0.8) are
summarized in Table 2 and Fig. 3. ROC curves corresponding to
the TB-specific responses of IL-13, IFN-, and IP-10 revealed
AUCs of 0.8409, 0.75, and 0.8848, respectively (Table 2), which
were statistically significant. However, the ratios of TB-specific to
mitogen-induced responses were associated with higher AUC val-
ues (0.8909, 0.8318, and 0.9242, respectively) that were also sta-
tistically significant compared to those of the TB-specific re-
sponses (Table 2). Importantly, the AUC for the IP-10 ratio
displayed the highest value among the AUCs for the tested param-
eters, including the TB-specific IP-10 response, indicating that the
IP-10 ratio is the most valuable diagnostic marker to discriminate
active TB versus LTBI. This tendency was still observed even
though we used tubes with different lot numbers, indicating that
our finding is not due to lot-to-lot differences (data not shown).
The TB-specific IP-10 levels were higher in active TB patients
than in LTBI subjects, whereas no differences were observed for
mitogen-induced levels between the two groups. The TB-specific
and mitogen-induced IP-10 levels were compared for each indi-
vidual to investigate the reason that the IP-10 ratio showed a
greater difference than the IP-10 level for TB antigen in discrimi-
nating active TB versus LTBI (Fig. 2B). Interestingly, most of the
active TB patients showed a higher response to TB antigen stim-
ulation but few to mitogen induction. However, healthy controls
and LTBI subjects had lower TB-specific than mitogen-induced
IP-10 levels, accounting for the significant difference in the IL-10
ratios between the groups.
The optimal cutoff values for the discrimination between ac-
tive TB versus LTBI were determined by ROC curve analysis and
are summarized in Table 3. The cutoffs for the median values of
TB-specific IL-13, IFN-, and IP-10 were 0, 172.84, and 23780.88,
respectively; these were able to discriminate 100%, 93.4%, and
69.7% of the true active TB patients (sensitivity) and 60%, 60%,
and 100%of the true LTBI subjects (specificity), respectively. Cut-
offs for the ratios of TB-specific to nonspecific responses were
0.0363, 0.0454, and 0.7906, respectively, and were able to discrim-
inate 78.79%, 87.88%, and 93.34% of the true active TB cases and
85%, 75%, and 90% of the true LTBI cases, respectively. Unex-
pectedly, the IP-10 cutoff value of 0.7906 was able to distinguish
between active TB and LTBI with 93.4% sensitivity and 90% spec-
ificity (Fig. 2C). Based on this optimal cutoff value, 31 of 33 active
TB patients were positively identified, but none of the non-TB
healthy controls and only 2 of 20 LTBI subjects were positive. The
2 active TB patients who were identified as negative had lower
TB-specific than mitogen-induced IP-10 levels, but no other un-
usual characteristics.
DISCUSSION
Commercial IGRAs such as the QFT-GIT are widely used to diag-
nose M. tuberculosis infection, but they cannot distinguish active
TB disease from LTBI (10, 27). In the current study, several cyto-
kines and chemokines were evaluated in active TB patients, LTBI
subjects, and non-TB healthy controls for their discriminatory
potential for the enhanced diagnosis of active TB infection com-
pared to that of the conventional QFT-GIT assay. In accordance
with previous findings, IL-2, IL-13, MIG, IP-10, and IFN- were
present at higher levels in active TB patients than in LTBI subjects
and non-TB healthy controls. In addition, IL-6 and IL-10, TNF-,
and I-TAG levels were higher in the active TB than in the LTBI
group. However, these markers were unable to distinguish be-
tween the groups accurately. Moreover, single cytokines may only
reflect inflammation; thus, mitogen-induced responses were as-
sumed to reflect the subjects’ immune status. When the ratio of
the TB-specific to mitogen-induced responses was calculated, ra-
tios for IL-13, IP-10, and IFN-were higher than the correspond-
ing values for TB antigen-stimulated responses. In particular, the
IP-10 ratio, when the optimal cutoff value was applied, identified
93.9% of the active TB and 90% of the LTBI subjects out of the
TB-related subjects.
Several studies tried to identify potential biomarkers for diag-
nosing active TB and discriminating between active TB and LTBI.
Wang et al. reported that the IL-2/IFN- ratio discriminated be-
tween active TB and LTBI with a sensitivity of 77.2% and a spec-
ificity of 87.2% (24). In addition, Frahm et al. reported that the
combination of IL-15 and MCP-1 identified active TB and LTBI
with a sensitivity of 83% and a specificity of 88% (18). In our
study, we found that the IP-10 ratio of TB-specific to mitogen-
induced responses displayed better sensitivity and specificity
(93.9% and 90%, respectively) in identifying active TB from LTBI
than other reported parameters. Therefore, the use of the IP-10
ratio might support an improved diagnosis of active TB disease
when combined with the standard diagnostic methods, including
microbiology,molecular tests, and clinical and radiological assess-
ments. IP-10 (also known as CXCL10 or IFN--induced protein
10) is a chemokine that is expressed at a high level in inflammatory
diseases such as systemic lupus erythematosus, thyroid disease,
acute coronary syndrome, and allergies (28–30). IP-10 is ex-
pressed in the bronchial epithelium (31) and in inflamed tissues
(32) of active TB patients, who demonstrate upregulation of the
helper T (Th) 1-type cytokine IFN-. IP-10 secretion may play an
important role in recruiting activated T cells, which is necessary
for protective immunity. In addition, chemokines and their recep-
tors, including IP-10, contribute to the formation and mainte-
nance of granulomas in TB (33). IP-10 plays a role inM. tubercu-
losis infection, and several studies have shown that antigen-
stimulated IP-10 responses have a sensitivity similar to that of
QFT-GIT for detecting active TB (12, 13, 34, 35). Our results also
showed a higher level of IP-10 in active TB patients, consistent
with previously published studies; IP-10 can therefore serve as a
potential diagnostic biomarker.
Since there is no gold standard for diagnosing LTBI, the bio-
marker studies to discriminate LTBI from active TB, including
Diagnostic Biomarker for Active TB
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our study, are often confronted with a difficulty in defining an
LTBI group. In the current study, we defined the LTBI group as
persons with no sign of active TB, who had close contact with
infectious TB patients and positive TST according to the Korean
TB guideline (25). Since 45% of the LTBI individuals defined in
our study were QFT negative, it would be worthwhile to compare
the responses after dividing the LTBI group into those who were
QFT positive and negative. Indeed, we found that the ratio of
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FIG 2 Ratio of TB-specific to mitogen-induced responses. Whole blood was stimulated withM. tuberculosis-specific antigens (ESAT-6, CFP-10, and TB7.7) or
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IP-10 in response to TB antigens and mitogen is higher in QFT-
positive than in QFT-negative individuals, suggesting that the TB
antigen-specific IFN- response and IP-10 production have a cer-
tain relation (see Fig. S1 in the supplemental material). However,
although we restricted the LTBI group to the persons positive for
both the TST and QFT, it was still obvious that the ratio of TB anti-
gen-induced and mitogen-induced IP-10 productions is the most
reliable parameter to discriminate between the LTBI individuals and
active TB patients with high values for both sensitivity and specificity
(see Table S1 in the supplemental material). These data indicate that
the method using the IP-10 ratio might be applicable to help in the
diagnosis for distinguishing active TB from LTBI, irrespective of the
QFT response in defining the LTBI group.
Apotentialdiagnosticbiomarker that is able todiscriminateactive
TB fromLTBI, depending on the IP-10 cutoff value,was identified in
this study. This parameter reflects individuals’ immune status,
thereby increasing the detection rate and improving diagnostic accu-
racy. Based on the bias in sensitivity and specificity evidenced by the
cutoff value, the ratio of TB-specific to mitogen-induced responses
might be a reliable diagnostic biomarker for active TB. Although ad-
ditional studies with a larger sample size are needed to confirm the
clinical utility of this ratio, these findings present a promising
method,which candiscriminatebetweenactiveTBandLTBI, to sup-
port the currentdiagnosticmethods forTB.Thispotential biomarker
might help the detection of patients with real active TB within 2 h
with improved sensitivity and specificity, thereby improving the ac-
curacy of diagnosis and advancing the time of therapy.
TABLE 2 AUC values obtained from the receiver operating
characteristic curve analysis
Analytical criteriona Targetb AUCc 95% CId P
TB Ag IL-13 0.8409 0.714–0.927 0.0001
IFN- 0.7500 0.612–0.859 0.002477
IP-10 0.8848 0.767–0.956 0.0001
TB Ag/mitogen ratio IL-13 0.8909 0.775–0.960 0.0001
IFN- 0.8318 0.704–0.920 0.0001
IP-10 0.9242 0.818–0.979 0.0001
a TB, tuberculosis; Ag, antigen,
b IL-13, interleukin-13; IFN-, interferon-gamma; IP-10, interferon gamma-induced
protein 10/chemokine (C-X-C) motif ligand-10.
c AUC, area under the curve.
d CI, confidence interval.
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FIG 3 ROC curves for TB-specific and mitogen-induced cytokine responses. The AUCs of TB-specific (A) and mitogen-induced (B) IL-13, IFN-, and IP-10
levels and the ratios of TB-specific to mitogen-induced responses (C) were compared between active TB patients and LTBI. The AUCs and the P values are
indicated on the graphs.
TABLE 3 Optimal cutoff values with associated sensitivities and
specificities to discriminate between LTBI and active TB
Analytical criteriona Targetb Cutoff Sensitivity (%) Specificity (%)
TB Ag IL-13 0 100 60
IFN- 172.84 93.94 60
IP-10 23,780.88 69.7 100
TB Ag/mitogen ratio IL-13 0.0363 78.79 85
IFN- 0.0454 87.88 75
IP-10 0.7906 93.94 90
a TB, tuberculosis; Ag, antigen,
b IL-13, interleukin-13; IFN-, interferon-gamma; IP-10, interferon gamma-induced
protein 10/chemokine (C-X-C) motif ligand-10.
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